Organon is a global pharmaceutical company focused on women’s health, biosimilars, and a portfolio of established medicines spun out of Merck. Its brands span contraception, fertility, menopause, and other therapies used by women across life stages, alongside biosimilar products in selected markets. The business model centers on commercializing mature and specialty brands rather than early discovery alone. Customers are patients, physicians, and health systems seeking accessible options in reproductive and broader women’s care.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1,594 | — | 145 | — |
| Q3 2025 | 1,602 | — | 160 | — |
| Q4 2025 | 1,507 | — | -205 | — |
| Q1 2026 | 1,460 | — | 146 | — |
| Q2 2026 | 1,558 | -2.3% | 108 | -25.5% |
All markets — KeepWinning global stock screener
Other companies on NYSE: SL Green Realty Corp. (SLG), Aris Mining Corporation (ARIS), LXP Industrial Trust (LXP), Cohen & Steers, Inc. (CNS), Avient Corporation (AVNT), Hamilton Insurance Group, Ltd. (HG)